Article
Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.
Drug discovery today - 1 May 2023
Rathod Lala S, Dabhade Pratap S, Mokale Santosh N
Abstract excerpt
KRASG12C has been identified as a potential target in the treatment of solid tumors. One of the most often transformed proteins in human cancers is the small Kirsten rat sarcoma homolog (KRAS) subunit of GTPase, which is typically the oncogene driver. KRASG12C is altered to keep the protein in an active GTP-binding form. KRAS has long been considered an 'undrugable' target, but sustained research efforts focusing...
Topics
- United States
- Humans
- Proto-Oncogene Proteins p21(ras)
- Lung Neoplasms
- Cysteine
- United States Food and Drug Administration
- Mutation